1167985-17-2

1167985-17-2 structure

Name: Ozoralizumab
Chemical Name: Ozoralizumab
CAS Number: 1167985-17-2
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-06-25 04:22:15
Modify Date: 2024-01-03 08:24:21
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1].

Name	Ozoralizumab

Description	Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1].
Related Catalog	Research Areas >> Inflammation/Immunology
In Vitro	Ozoralizumab (ATN-103; 0-1000 pM; 48 h) 在 L929 细胞细胞毒性试验中具有高 TNFα 中和效力，对人 TNFα 和猴 TNFα 的 KD 值分别为 20.2 pM 和 16.1 pM[1]。
In Vivo	Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 人 TNF 转基因小鼠) 抑制关节炎并降低关节炎评分[1]。 Animal Model: Tg197 human TNF transgenic mice[1] Dosage: 1 mg/kg Administration: Subcutaneous injection Result: Reduced the mean histopathologic score in the Tg197 mice. Had ability to neutralize TNFα activity.
References	[1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008.

No Any Chemical & Physical Properties